Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
International Journal of Clinical Oncology · August 11, 2026
Well-designed and adequately powered for the question it asks.
In Japanese patients with metastatic NSCLC and tumor PD-L1 < 1%, nivolumab plus ipilimumab with or without chemotherapy versus chemotherapy alone produced a clinically meaningful OS improvement (HR 0.46, 95% CI 0.27–0.78) with 5-year OS rates of 38% versus 16%. This pooled subgroup analysis extends global trial results to a population with high unmet medical need, though the Japanese sample is relatively small.
Randomized, phase 3 pooled subgroup analysis (CheckMate 227 and CheckMate 9LA). Japanese patients enrolled in CheckMate 227 and CheckMate 9LA with stage IV or recurrent metastatic NSCLC, tumor PD-L1 expression < 1%, and no sensitizing EGFR or ALK alterations.. Intervention: Nivolumab plus ipilimumab with or without chemotherapy (2 cycles). Compared with: Chemotherapy alone (≤4 cycles). n = 75. Japan (subset of global trials CheckMate 227 and CheckMate 9LA).
Median OS 41.0 months (95% CI 19.4-NR) versus 15.2 months (95% CI 7.6–21.3) with HR 0.46 (95% CI 0.27–0.78) 5-year OS rates 38% (95% CI 22–54) versus 16% (95% CI 6–30) Median PFS 8.2 months (95% CI 4.1–19.3) versus 5.6 months (95% CI 4.2–7.0) with HR 0.57 (95% CI 0.31–1.03)
Source does not report objective response rate, duration of response, or detailed safety event rates despite stating these were assessed No new safety signals observed
For clinicians treating Japanese patients with metastatic NSCLC and low PD-L1 expression (< 1%), this analysis provides evidence that nivolumab plus ipilimumab-based therapy offers substantial long-term OS benefit over chemotherapy alone, supporting its use as first-line treatment in this population with historically poor prognosis. The durability (5-year OS 38%) is clinically significant, though the modest Japanese subgroup size warrants consideration alongside the global trial results.
Rigorous phase 3 pooled analysis demonstrating a clinically meaningful OS benefit (HR 0.46) with durable 5-year survival gains in a population with high unmet need and poor prognosis, though sample size in the Japanese subgroup is modest.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians treating Japanese patients with metastatic NSCLC and low PD-L1 expression (< 1%), this analysis provides evidence that nivolumab plus ipilimumab-based therapy offers substantial long-term OS benefit over chemotherapy alone, supporting its use as first-line treatment in this population with historically poor prognosis. The durability (5-year OS 38%) is clinically significant, though the modest Japanese subgroup size warrants consideration alongside the global trial results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-line nivolumab plus ipilimumab with or without chemotherapy (2 cycles) versus chemotherapy (≤ 4 cycles) in a pooled population of Japanese patients with metastatic NSCLC and tumor PD-L1 < 1% from the randomized, phase 3 CheckMate 227 (NCT02477826) and CheckMate 9LA (NCT03215706) studies. METHODS: Adults with stage IV/recurrent NSCLC without sensitizing EGFR/ALK alterations were included. Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. RESULTS: Among the pooled population of Japanese patients with tumor PD-L1 < 1% in the nivolumab plus ipilimumab with or without chemotherapy (n = 34) versus chemotherapy (n = 41) arms, median OS was 41.0 (95% CI 19.4-not reached) versus 15.2 (95% CI 7.6-21.3) months (hazard ratio [HR] 0.46; 95% CI 0.27-0.78); 5-year OS rates were 38% (95% CI 22-54) versus 16% (95% CI 6-30). Median PFS was 8.2 (95% CI 4.1-19.3) versus 5.6 (95% CI 4.2-7.0) months (HR 0.57 [95% CI 0.31-1.03]). No new safety signals were observed. CONCLUSIONS: Consistent with results in the pooled global population, nivolumab plus ipilimumab with or without chemotherapy showed long-term, durable clinical benefit in Japanese patients with metastatic NSCLC and tumor PD-L1 < 1%, suggesting potential clinical benefit with its use as a first-line treatment for this hard-to-treat population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.